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Interleukin (IL)-11 has been shown to be a crucial
factor for intestinal tumorigenesis, lung carcinomas,
and asthma. IL-11 is thought to exclusively mediate
its biological functions through cell-type-specific
expression of the membrane-bound IL-11 receptor
(IL-11R). Here, we show that the metalloprotease
ADAM10, but not ADAM17, can release the IL-11R
ectodomain. Chimeric proteins of the IL-11R and
the IL-6 receptor (IL-6R) revealed that a small juxta-
membrane portion is responsible for this substrate
specificity of ADAM17. Furthermore, we show that
the serine proteases neutrophil elastase and protein-
ase 3 can also cleave the IL-11R. The resulting solu-
ble IL-11R (sIL-11R) is biologically active and binds
IL-11 to activate cells. This IL-11 trans-signaling
pathway can be inhibited specifically by the anti-
inflammatory therapeutic compound sgp130Fc. In
conclusion, proteolysis of the IL-11R represents a
molecular switch that controls the IL-11 trans-
signaling pathway and widens the number of cells
that can be activated by IL-11.
INTRODUCTION
Cytokines of the interleukin (IL)-6 family are critically involved in
health and disease, fulfilling pro- as well as anti-inflammatory
functions (Garbers and Scheller, 2013; Scheller et al., 2014).
IL-11, one of its members, can be secreted upon stimulation
by a variety of cells, including epithelial cells of the lung and
the gastrointestinal tract, or fibroblasts of skin and lung (Putoczki
and Ernst, 2015). Upon secretion, IL-11 binds to a membrane-
bound IL-11R, which is expressed in a cell-type-specific manner
and has been detected in many organs, e.g., bone, heart, lung,
spleen, gastrointestinal tract, and uterus (Davidson et al., 1997;
Garbers and Scheller, 2013; Putoczki and Ernst, 2015). After for-
mation of the IL-11/IL-11 receptor (IL-11R) complex, signaling is
initiated through recruitment of two molecules of the commonCell Rb-receptor gp130, which leads to the activation of the Janus ki-
nase/signal transducer and activator of transcription (Jak/STAT)
pathway and the mitogen-activated protein kinase (MAPK)
cascade.
Overshooting activities of IL-11 have been shown to be
critically involved in the development of epithelial cancers (Na-
kayama et al., 2007), especially in gastrointestinal tumorigenesis
in mice and humans (Ernst et al., 2008; Ernst and Putoczki, 2014;
Howlett et al., 2009; Putoczki et al., 2013). Genetic depletion of
the IL-11R or treatment with an inhibitory IL-11 mutein was suf-
ficient to prevent IL-11-dependent tumor formation (Ernst et al.,
2008; Putoczki et al., 2013). Furthermore, IL-11 has a profound
role in the lung (Garbers and Scheller, 2013). Transgenic expres-
sion of IL-11 under a lung-specific promoter led to lung fibrosis
and airway obstruction (Tang et al., 1996), mimicking the pathol-
ogy found in human asthma patients, where IL-11 expression
correlates with disease severity (Minshall et al., 2000).
Besides IL-11, IL-6 is the only other cytokine of the family
that signals via a gp130 homodimer. Signaling can be initi-
ated through membrane-bound IL-6 receptor (IL-6R) (classic
signaling), which is mainly found on hepatocytes and several
leukocyte subsets, and soluble forms of the IL-6R (trans-
signaling). IL-6 binds to the soluble and the membrane-bound
IL-6R with similar affinity, and both complexes activate cells
via gp130 homodimerization (Jostock et al., 2001; Taga et al.,
1989). Due to the ubiquitous expression of gp130, IL-6 trans-
signaling can activate virtually all cells of the body, and this
mainly accounts for the pro-inflammatory properties of the cyto-
kine (Rose-John, 2012). Consequently, the specific inhibition of
IL-6 trans-signaling via a dimerized variant of soluble gp130
(sgp130Fc) has been shown to be sufficient to block IL-6-driven
inflammatory diseases (Jones et al., 2011). Selective blockade of
IL-6 trans-signaling might be even superior compared to global
IL-6 inhibition, and an optimized sgp130Fc variant is currently
in clinical development.
Soluble forms of the IL-6R are found in human serum at high
concentrations of about 30–70 ng/ml and are either generated
by alternative splicing of the IL-6R mRNA (10%) or by limited
proteolysis of membrane-bound protein precursors (90%),
also known as ectodomain shedding (Chalaris et al., 2011). Ma-
jor proteases of the IL-6R are the twometalloproteases ADAM10eports 14, 1761–1773, February 23, 2016 ª2016 The Authors 1761
Figure 1. The IL-11R Is No Substrate for ADAM17
(A) HEK293 cells were transiently transfected with a plasmid encoding the human IL-6R and treatedwith 100 nMPMA for 2 hr. Soluble receptors in the cell-culture
supernatant were analyzed by ELISA. The amount of soluble receptor without stimulation was set to 1, and the increase after PMA stimulation was calculated
accordingly (n = 3, mean ± SD). *p < 0.05.
(B) The experiment was performed as described in (A), but the cells were pre-treated for 30 min with the metalloprotease inhibitors GI and GW where indicated.
Soluble IL-6R was precipitated from cell-culture supernatant and visualized by western blot. Cells were lysed, and IL-6R expression was also determined via
western blot. GAPDH served as loading control. Western blots from three independent experiments were quantified (mean ± SD). *p < 0.05.
(C and D) HEK293 cells were transiently transfected with a plasmid encoding the human IL-11R, and experiments were performed as described for (A) and (B).
Error bars indicate mean ± SD. ns, not significant.
(legend continued on next page)
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and ADAM17, which release the IL-6R ectodomain from
cells (Baran et al., 2013; Garbers et al., 2011a; Matthews
et al., 2003). However, the neutrophil-derived serine protease
cathepsin G (CG) is also capable of cleaving the IL-6R (Bank
et al., 1999). Despite the detection of an mRNA that encodes a
soluble IL-11R (sIL-11R) (Robb et al., 1996), no natural soluble
forms of the IL-11R have been described. In vitro experiments
with recombinant proteins have shown, however, that IL-11, in
combination with sIL-11R, is an agonistic cytokine that induces
signaling in cells that do not respond to IL-11 alone (Dams-
Kozlowska et al., 2012; Kurth et al., 1999; Pflanz et al., 1999).
In this report, we show that the IL-11R is a substrate for
ADAM10, but cannot be cleaved by the related protease
ADAM17, and we identify structural traits for this substrate
specificity. The cleaved sIL-11R binds IL-11 and induces cellular
proliferation via gp130 in a STAT3-dependent manner, which
can be completely and specifically blocked by the IL-6 trans-
signaling inhibitor sgp130Fc. Finally, we identify the neutrophil
serine proteases neutrophil elastase (NE) and proteinase 3
(PR3) as additional sheddases of the IL-11R. In conclusion, we
describe a protease regulation of the IL-11 trans-signaling
pathway that widens the spectrum of cells that can be activated
by IL-11.
RESULTS
The IL-11R Is Not a Substrate for the Metalloprotease
ADAM17
It is well established that IL-6 can signal through membrane-
bound as well as soluble forms of the IL-6R and that these two
modes of signaling possess striking differences with regard to
pathophysiology (Scheller et al., 2011b). Surprisingly, no natural
soluble forms of the IL-11 receptor a have been described to
date; thus, IL-11 is thought to act solely via its membrane-bound
IL-11R. To elucidate whether an sIL-11R could be generated, we
investigated the proteolysis of the membrane-bound IL-11R by
members of the ADAM family of proteases. We focused on
ADAM17, which is the major protease of the IL-6R. To compare
the proteolyses of IL-6R to that of IL-11R, we first expressed
IL-6R in HEK293 cells and stimulated themwith the phorbolester
phorbol 12-myristate 13-acetate (PMA), the strongest known
activator of ADAM17. We detected a significant 4.3- ± 1.3-fold
increase in sIL-6R generation after PMA stimulation, using an
IL-6R-specific ELISA (Figure 1A), which was confirmed by west-
ern blotting of precipitated receptor from the cell supernatant
(Figure 1B). Pre-incubation with the ADAM10-specific inhibitor
GI254023X (GI) did not block IL-6R proteolysis, but the com-
bined ADAM10/17-specific inhibitor GW280264X (GW) was
able to completely abolish PMA-induced shedding, thus con-
firming ADAM17 as the PMA-induced protease of the IL-6R (Fig-
ure 1B) (Garbers et al., 2011a; M€ullberg et al., 1993). In contrast,
HEK293 cells transfected with an IL-11R expression plasmid(E) HeLa cells were transiently transfected with either IL-6R or IL-11R. Cells we
stained. Cytokine receptors are stained in red, and the nucleus is stained in blue
(F) THP-1 cells were stimulated with 100 nM PMA with or without pretreatment
surface were analyzed via flow cytometry.
See also Figure S1.
Cell Rshowed no significant increase in sIL-11R after PMA stimulation
for 2 hr (0.8- ± 0.6-fold; Figure 1C). In line with this, we could not
precipitate sIL-11R from cell-culture supernatant (Figure 1D).We
detected some sIL-11R after longer stimulation with PMA for up
to 24 hr (Figure S1A). However, the amounts were negligible
compared to sIL-6R generation (Figures S1B and S1C). We veri-
fied our observations by overexpression of both receptors in
HeLa cells. IL-6R and the IL-11R were localized at the plasma
membrane (Figure 1E). The IL-6R was lost from the cell surface
upon PMA stimulation, which could be prevented by pre-incuba-
tion with GW but not with GI. In contrast, stimulation of ADAM17
by PMA did not alter the IL-11R levels at the plasma membrane,
which confirms that the IL-11R is usually not a substrate for
ADAM17 (Figure 1E). As a final proof, we investigated limited
proteolysis after PMA stimulation on cells expressing both cyto-
kine receptors endogenously. The human monocytic cell line
THP-1 expresses IL-6R and IL-11R (Jones et al., 1998; Karjalai-
nen et al., 2015), and only the IL-6Rwas lost from the cell surface
upon stimulation with PMA, which was, again, sensitive toward
GW-mediated inhibition of ADAM17 (Figure 1F). In conclusion,
we provide evidence that the IL-11R is not a substrate for the
metalloprotease ADAM17.
The Stalk Regions of IL-6R and IL-11R Determine
Susceptibility toward Cleavage by ADAM17
To determine which regions are responsible for the difference in
the proteolytic processing observed between IL-6R and IL-11R,
we constructed four chimeric receptors based on the IL-6R
(Figure 2A). We replaced the transmembrane region (termed
IL-6R-TM), the intracellular region (IL-6R-ICD), the stalk region
(IL-6R-S), or just the ten juxtamembrane amino acid residues
Val-356 to Pro-365 (IL-6R-10AS) with their IL-11R counterparts.
When transfected in HEK293 cells, both IL-6R-TM and IL-6R-
ICD were shed after stimulation with PMA, as analyzed by ELISA
and western blot (Figures 2B–2E), indicating that neither the
transmembrane nor the intracellular regions of the IL-6R and
the IL-11R were important for ADAM17 to discriminate between
substrate and non-substrate. This is in line with previous studies
showing that the intracellular domain of the IL-6R is dispensable
for PMA-mediated shedding (Garbers et al., 2011a; M€ullberg
et al., 1993). In contrast, IL-6R-S was resistant toward proteoly-
sis by ADAM17 (1.2- ± 0.2-fold increase; Figure 2F), which sug-
gests that a motif within the stalk region of the IL-11R prevents
ADAM17-mediated proteolysis and that this can be transferred
to the IL-6R. Because the cleavage site of ADAM17 within the
IL-6R stalk is known (M€ullberg et al., 1994), we swapped only
ten amino acid residues from the IL-6R, which included its
cleavage site Asp-358/Gln-359, with their IL-11R counterpart
(IL-6R-10AS). As shown in Figure 2G, stimulation of IL-6R-
10AS-transfected HEK293 cells with PMA resulted in an 1.1- ±
0.1-fold increase, demonstrating that this mutation was suffi-
cient to efficiently prevent proteolysis by ADAM17. These datare grown on coverslips for 48 hr, stimulated as indicated, and were fixed and
(DAPI). Scale bars, 10 mm.
with the protease inhibitors GI or GW, and cytokine receptor levels at the cell
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Figure 2. The Stalk Region of the IL-6R Determines Its Cleavage Specificity
(A) Schematic overview of the IL-6R and chimeric variants thereof. IL-6R and IL-11R share the same overall topology, consisting of an immunoglobulin (Ig)-like
domain (D1), two fibronectin type III domains (D2 andD3), a stalk (S) region, a transmembrane (TM) region, and an intracellular domain (ICD). The IL-6R is depicted
in orange, whereas regions originating from the IL-11R are shown in blue. The values shown besides the chimeras are the x-fold increase after PMA stimulation
(mean ± SD, n = 3). To calculate this, the amount of constitutively shed IL-6R or chimera was measured by ELISA and arbitrarily set to 1. The increase after
stimulation with PMA was calculated accordingly. Chimeras with at least a 2-fold increase in soluble receptor formation were defined as good substrates for
ADAM17 (colored in green), whereas chimeras with values below this were considered weak substrates (colored in red).
(B–G) HEK293 cells were transiently transfected with plasmids encoding IL-6R-TM (B and C), IL-6R-ICD (D and E), IL-6R-S (F), or IL-6R-10AS (G), and the amount
of shedding upon PMA stimulation was analyzed by ELISA and western blot, as described in the legend for Figure 1 (mean ± SD). *p < 0.05; ns, not significant.
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show that replacement of the ADAM17 cleavage site by the
corresponding amino acid residues of a non-substrate is suffi-
cient to render the IL-6R unresponsive toward proteolysis by
ADAM17.
In light of these results, we sought to analyzewhether we could
generate an IL-11R mutant that is a substrate for ADAM17. To
this end, we first transferred the transmembrane region from
the IL-6R to the IL-11R (termed IL-11R-TM; Figure 3A) and
analyzed proteolysis in transfected HEK293 cells. Although we
observed a 1.9- ± 0.3-fold increase in sIL-11Rwhen we analyzed
the supernatant of cells stimulated with PMA (Figure S2A), we
could not detect sIL-11R via western blotting after precipitation
(Figure S2B). Furthermore, exchange of the intracellular region
(IL-11R-ICD) did not result in increased susceptibility toward
cleavage by ADAM17 (Figures S2C and S2D). This strongly
argues against a role for these two regions, with regard to the
substrate specificity of ADAM17, and confirms our results ob-
tained with IL-6R-TM and IL-6R-ICD (Figures 2B–2E).
In contrast, combined transfer of the stalk, the transmem-
brane, and the intracellular region (IL-11R-S/T/I) or of the stalk
region alone (IL-11R-S) resulted in significant cleavage of the
IL-11R after PMA stimulation, whichwas reduced to background
levels by treatment with the combined ADAM10/17 inhibitor
GW, but not the ADAM10-specific inhibitor GI (Figures 3B and
3C). Strikingly, transfer of ten amino acid residues (Asp-361 to
Ala-370, IL-11R-10AS) was sufficient to convert the IL-11R into
a substrate for ADAM17 (Figures 3D and 3E). These results indi-
cate that the cleavage site within the stalk region is the critical
determinant that distinguishes between substrate and non-sub-
strate. Importantly, this cleavage specificity could be swapped
between IL-6R and IL-11R through the exchange of only ten
amino acid residues.
The IL-11R Is Cleaved by ADAM10
The human IL-6R is a substrate not only for ADAM17 but also
for its close homolog ADAM10 (Garbers et al., 2011a; Matthews
et al., 2003). Cellular influx of calcium, mediated by the iono-
phore ionomycin, is a strong activator of ADAM10-mediated
IL-6R shedding (Garbers et al., 2011a; Jones et al., 1998). There-
fore, we sought to investigate whether the IL-11R might also
be a substrate for ADAM10. First, we verified ADAM10-mediated
shedding of the IL-6R after stimulation with ionomycin. HEK293
cells transiently transfected with IL-6R showed ADAM10-medi-
ated proteolysis of the IL-6R, which could be blocked completely
by both GI and GW (Figure 4A). Interestingly, we could detect
sIL-11R in the supernatant of ionomycin-stimulated HEK293
cells that were transiently transfected with IL-11R (Figure 4B).
Generation of the soluble IL-11R ectodomain was significantly
diminished when the cells were pre-incubated with GI or GW,
strongly arguing for ADAM10 as the responsible protease
(Figure 4B).
In order to not solely rely on pharmacological inhibitors,
we made use of murine embryonic fibroblasts (MEFs) deficient
for either ADAM10 (A10/), ADAM17 (A17/), or both
(A10//A17/). As a control, we first stimulated wild-type
MEFs transiently transfected with IL-11Rwith ionomycin and de-
tected sIL-11R generation (Figure 4C). Proteolysis of the IL-11R
and subsequent sIL-11R detection in the cell supernatant wasCell Rsignificantly diminished in A10/ MEFs, which was accompa-
nied by elevated amounts of full-length uncleaved IL-11R in the
cell lysate (Figure 4C). Stimulation of A17/MEFs with ionomy-
cin revealed unaltered sIL-11R generation indistinguishable from
wild-type MEFs (Figure 4C). In contrast, we could barely detect
sIL-11R in the supernatant of stimulated A10//A17/ MEFs.
Moreover, full-length IL-11R expression in the cell lysate was
greatly increased, resembling the findings in the A10/ MEFs
and further strengthening the finding that ADAM10 is the domi-
nant sheddase of the IL-11R. In line with this, stimulation with
ionomycin led to the loss of cell-surface expression of both
IL-6R and IL-11R in transfected HeLa cells, which could be
prevented by both GI and GW (Figure 4D). Furthermore, activa-
tion of ADAM10 led to proteolysis of endogenous IL-6R and
IL-11R in THP-1 cells (Figure 4E). Taken together, our data
identify ADAM10 as a potent sheddase of the IL-11R.
Arg-355 Is Important for ADAM10-Mediated Cleavage of
the IL-11R
In order to identify the cleavage site within the IL-11R that is used
by ADAM10, we generated three mutants of the IL-11R that
contained successive deletions of ten amino acid residues
each in the juxtamembrane part of the stalk region (Figure 5A).
Removal of the ten amino acid residues Val-363 to Leu-372
(IL-11RDV363_L372) directly adjacent to the plasma membrane
did not influence ionomycin-induced proteolysis of the IL-11R
compared to thewild-type (Figure 5B).We observed significantly
reduced IL-11R shedding when we deleted the next ten amino
acid residues His-353 to Ser-362 (IL-11RDH353_S362), but we
found unaltered proteolysis when the adjacent ten amino acid
residues Pro-343 to Pro-352 (IL-11RDP343_P352) were deleted,
suggesting that the ADAM10 cleavage site is located between
His-353 and Ser-362 (Figure 5B). Profiling of ADAM10 cleavage
sites has revealed a strong preference for arginine residues
within the cleavage site, which is not the case for ADAM17
(Tucher et al., 2014). Indeed, when we mutated Arg-355 to a glu-
tamic acid (IL-11R_R355E), which is disfavored in ADAM10
cleavage sites (Tucher et al., 2014), we observed significantly
reduced proteolysis of the IL-11R of just 30.9% ± 11.7%,
compared to wild-type IL-11R (Figures 5C and 5D; Figure S3B),
despite comparable cell-surface expression (Figure S3A). These
results suggest that Arg-355 is critical for proteolysis of the
IL-11R by ADAM10.
IL-11 Trans-signaling Is Specifically Blocked by
sgp130Fc
It has been shown previously that a fusion protein of IL-11 and
the IL-11R ectodomain acts as an agonistic cytokine on
gp130-expressing cells (Dams-Kozlowska et al., 2012; Kurth
et al., 1999; Pflanz et al., 1999). We recapitulated this with re-
combinant IL-11 and sIL-11R, which were able to stimulate the
proliferation of Ba/F3-gp130 cells in a concentration-dependent
manner (Figure 6A). Importantly, this mode of IL-11 trans-
signaling could be completely and selectively blocked by
sgp130Fc (Figure 6B), a designer protein developed previously
to block IL-6 trans-signaling through binding and, thus, neutral-
ization of the agonistic IL-6/sIL-6R complex (Garbers et al.,
2011b; Jones et al., 2011; Jostock et al., 2001). IL-11-driveneports 14, 1761–1773, February 23, 2016 ª2016 The Authors 1765
Figure 3. Susceptibility toward Cleavage by ADAM17 Can Be Transferred from the IL-6R to the IL-11R
(A) Schematic overview of the IL-11R and chimeric variants thereof. IL-6R and IL-11R share the same overall topology, consisting of an immunoglobulin (Ig)-like
domain (D1), twofibronectin type III domains (D2andD3), a stalk (S) region, a transmembrane (TM) region, andan intracellular domain (ICD). The IL-11R isdepicted in
blue, whereas regions originating from the IL-6R are shown in orange. The values shown beside the chimeras are the x-fold increase after PMA stimulation (mean ±
SD, n = 3). To calculate this, the amount of constitutively shed IL-11R or chimera wasmeasured by ELISA and arbitrarily set to 1. The increase after stimulation with
PMA was calculated accordingly. Chimeras with at least a 2-fold increase in soluble receptor formation were defined as good substrates for ADAM17 (colored in
green), whereas chimeras with values below this were considered weak substrates (colored in red). IL-11R-S/T/I and IL-11R-S could not be detected via ELISA.
(B–E) HEK293 cells were transiently transfected with plasmids encoding IL-11R-S/T/I (B), IL-11R-S (C), or IL-11R-10AS (D and E), and the amount of shedding
upon PMA stimulation was analyzed by ELISA and western blot as described in the legend to Figure 1 (mean ± SD; n = 3). *p < 0.05.
See also Figure S2.
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proliferation of Ba/F3-gp130-IL-11R cells was not blocked by
sgp130Fc (Figures S4A and S4B). To test whether sIL-11R pro-
duced by ectodomain shedding was also able to signal in com-
bination with IL-11, we used a supernatant of HEK293 cells that
were transiently transfected with IL-11R cDNA. The supernatant
of ionomycin-stimulated cells induced significantly enhanced
proliferation of Ba/F3-gp130 cells when IL-11 was added, but
not without the cytokine (Figure 6C). Inhibition of ADAM10 with
GI or GW prior to ionomycin stimulation not only prevented
IL-11R shedding (Figure 4B) but also resulted in significantly
less proliferation in this assay (Figure 6C), demonstrating that
the released IL-11R ectodomain is, indeed, biologically active.
Addition of sgp130Fc to supernatant containing sIL-11R and
IL-11, representing protease-controlled, natural IL-11 trans-
signaling, blocked the proliferation of Ba/F3-gp130 cells signifi-
cantly in a dose-dependent manner (Figure 6D) and prevented
the phosphorylation of STAT3 (Figure 6E).
Taken together, our data show that IL-11, in complex with the
proteolytically generated sIL-11R, is a biologically active com-
posite cytokine, which can induce signaling and proliferation in
a gp130-dependent manner.
Neutrophil-Derived Serine Proteases Cleave IL-6R and
IL-11R
Besides cleavage by ADAM10 and ADAM17, the IL-6R can also
be shed by the neutrophil-derived serine protease CG, but not by
NE or PR3 (Bank et al., 1999). To verify this finding, we incubated
HepG2 cells with increasing amounts of the three proteases and
measured the release of the endogenous IL-6R into the superna-
tant via ELISA. Indeed, only CG was able to generate sIL-6R in a
dose-dependent manner (Figure 7A). To investigate a possible
role for these proteases in sIL-11R generation, we stained hu-
man primary CD66b+ polymorphonuclear leukocytes (PMNs)
and found a high expression of IL-11R on these cells (Figure 7B;
Figure S5), indicating that secreted neutrophil proteases could,
indeed, target the IL-11R in vivo. We further transiently trans-
fected HEK293 cells with a cDNA encoding the IL-11R and
added different amounts of purified proteases to the cells. As
shown in Figure 7C, high concentrations of NE (1,000 ng/ml; Fig-
ure 7C, NE section at left, white arrowhead) were, indeed, able to
shed the IL-11R. In contrast, we did not detect a significant in-
crease in sIL-11R generation when we incubated the cells with
CG (Figure 7C, CG section in the middle). PR3 was, however,
also able to shed the IL-11R, even at rather low concentrations
of 250 ng/ml (Figure 7C, PR3 section at right, white arrowhead).
Interestingly, the molecular weight of the sIL-11R derived from
cleavage by NE and PR3 appeared to be lower compared to
the sIL-11R generated by ADAM10-mediated constitutive cleav-
age (Figure 7C, black arrowhead), suggesting different cleavage
sites. Supernatant from IL-11R- or IL-6R-transfected cells
induced proliferation of Ba/F3-gp130 when combined with the
appropriate cytokine, confirming that the constitutively released
receptors by ADAM10 are biologically active (Figures 7D and
7E). However, also both NE-shed sIL-11R and CG-shed sIL-6R
were biologically active, as they significantly enhanced prolifera-
tion (Figures 7D and 7E). These data show that neutrophil serine
proteases are principally able to cleave both IL-6R and IL-11R,
albeit with different specificity toward these two substrates.Cell RIn order to investigate a possible IL-11 trans-signaling in vivo,
we collected serum from 21 healthy volunteers and analyzed
cytokine and cytokine receptor levels via ELISA. IL-6 and IL-11
levels were in the low picogram range, as expected (Figures 7F
and 7G), and sIL-6R levels were between 40 and 80 ng/ml (Fig-
ure 7H), as shown before (Garbers et al., 2014). Interestingly,
we detected sIL-11R in 9 out of 21 serum samples in a range
between 20 pg/ml and 4 ng/ml (Figure 7I). These data show
that sIL-11R exists in human blood, and they open up the possi-
bility that IL-11 trans-signaling occurs in vivo.
DISCUSSION
Limited proteolysis ofmembrane-bound protein precursors, also
known as ectodomain shedding, is an important post-transla-
tional modification that is, in contrast to methylation or phos-
phorylation, completely irreversible (Khokha et al., 2013; Murphy
et al., 2008). Shedding results in loss of cell-surface expression
of the protease substrates, and the newly generated soluble
ectodomains can fulfill own distinct biological functions, acting
either as agonists or antagonists. Recent data show that 10%
of all proteins on the plasma membrane of platelets can be
shed by proteases (Fong et al., 2011), and it is likely that this is
also true for other cell types. Among the plethora of 566 pre-
dicted proteolytic enzymes in the human genome, the twometal-
loproteases ADAM10 and ADAM17 have emerged as important
proteases in vivo, with non-redundant functions. ADAM10 is the
main secretase for the Notch pathway, and ADAM17 cleaves
tumor necrosis factor (TNF)a, as well as several ligands of the
epidermal growth factor receptor. Until now, more than 100 sub-
strates are known that are to be cleaved solely by ADAM10,
ADAM17, or both (Scheller et al., 2011a). Genetic depletion of
either of these proteases in mice results in embryonic lethality
(Hartmann et al., 2002; Peschon et al., 1998).
It is well established that IL-6 can signal via membrane-bound
and soluble forms of the IL-6R, and the latter one is predomi-
nantly generated via limited proteolysis (Chalaris et al., 2011;
Garbers et al., 2015; Scheller et al., 2014). Soluble IL-6R is found
in human serum at high concentrations of about 30–70 ng/ml. In
the present study, we show also that the receptor of its closest
family relative, IL-11, can undergo ectodomain shedding.
Whereas the IL-6R can be shed by ADAM10 and ADAM17, our
experiments with heterologous and endogenously expressed
IL-11R revealed that only ADAM10 is capable of cleaving the
IL-11R.
With the help of chimeric receptors, in which we exchanged
different parts between IL-6R and IL-11R, we could show that
transfer of the stalk region was sufficient to reverse this cleavage
specificity. Moreover, transfer of ten amino acid residues, which
contain the IL-6R cleavage site, were sufficient to generate an
IL-11R that could be cleaved by ADAM17, and the correspond-
ing IL-6Rmutant containing the respective part of the IL-11Rwas
resistant toward induced proteolysis by ADAM17. Thus, it ap-
pears that only the absence of an ADAM17 cleavage site within
the IL-11R stalk prevents effective proteolysis of the IL-11R
and that no further structural or regulatory elements would be
required. We have previously shown that the so-called CANDIS
region of ADAM17 binds to the region between Glu-317 andeports 14, 1761–1773, February 23, 2016 ª2016 The Authors 1767
Figure 4. ADAM10 Cleaves the IL-11R
(A and B) HEK293 cells were transiently transfected with plasmids encoding the human IL-6R (A) or the human IL-11R (B) and stimulated with 1 mM ionomycin
(Iono) for 1 hr, with or without pre-incubation with the ADAM inhibitors GI or GW. Soluble receptors were precipitated from cell-culture supernatant and visualized
by western blot. Cells were lysed, and the lysates were also analyzed by western blot. GAPDH served as loading control. Western blots from three independent
experiments were quantified (mean ± SD). *p < 0.05.
(legend continued on next page)
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Figure 5. Arginine-355 Is Required for
ADAM10-Mediated Shedding of the IL-11R
(A) Schematic overview of the IL-11R and deletion
variants thereof. The amino acid sequence from
Ser-316 to Ile-374 is shown, with the sequence of
the stalk region highlighted in blue. The range of
each deletion is shown in front of the schematic
drawing.
(B) HEK293 cells were transiently transfected with
plasmids encoding the human IL-11R or deletion
variants thereof and stimulated with ionomycin
(Iono) for 1 hr where indicated. Soluble receptors
were precipitated from cell-culture supernatant
and visualized by western blot. Cells were
lysed, and the lysates were also analyzed by
western blot. GAPDH served as loading control.
Western blots from three independent experi-
ments were quantified (mean ± SD). *p < 0.05; ns,
not significant.
(C) HEK293 cells were transiently transfected with
IL-11R or the R355E mutant, and ectodomain
shedding was analyzed. Experiments were per-
formed as described for (B), but cells were pre-
incubated with the protease inhibitors GI or GW
where indicated. One representative western blot
is shown.
(D) Relative proteolysis of (C) (mean ± SD).
*p < 0.05.
See also Figure S3.Gln-332 within the IL-6R stalk and that deletion of these amino
acid residues significantly, albeit not completely, reduces
IL-6R shedding (D€usterho¨ft et al., 2014). Binding of CANDIS to
the IL-11R appears not to be essential for IL-11R proteo-
lysis, although it is tempting to speculate that transfer of the
CANDIS-binding region, in addition to the cleavage site, into
IL-11R might enhance ADAM17-mediated proteolysis.
Cleavage by ADAM10 results in the release of the IL-11R
ectodomain. Although it is known that ADAM proteases cleave
extracellularly in the juxtamembrane part of their substrates,
the establishment of consensus cleavage sites for ADAM
proteases has been difficult (Caescu et al., 2009). Our deletion
variant IL-11RDH353_S362 shows strongly reduced shedding
by ADAM10, suggesting that ADAM10 cleaves within this region.(C) MEFs from wild-type (wt) animals and from mice deficient in ADAM10, ADAM17, or both proteases w
stimulated, and shedding was analyzed by western blots as described for (A) and (B). Western blots from three
SD). *p < 0.05; ns, not significant.
(D) ADAM10-mediated proteolysis of IL-6R and IL-11R in HeLa cells was analyzed as described in the lege
(E) THP-1 cells were stimulated with 1 mM ionomycin, and the amount of cytokine receptor at the cell surfac
Cell Reports 14, 1761–1773, FRecent data obtained with proteome-
derived peptide libraries revealed a pref-
erence of ADAM10 for arginine residues
at the P1 and/or P10 position of the cleav-
age site (Tucher et al., 2014). Indeed,
mutation of Arg-355 to a glutamic acid
residue was sufficient to significantly
reduce proteolysis of the IL-11R to
30.9% ± 11.7% compared to the wild-
type, strengthening the notion that cleav-age by ADAM10 occurs at this site. The cleavage site of ADAM10
within the IL-6R has not been determined yet (Baran et al., 2013).
Similar to ADAM17 and ADAM10, neutrophil-derived serine
proteases show differential cleavage specificity for IL-6R and
IL-11R. The IL-6R can be shed by CG (Bank et al., 1999). In
contrast, this protease is not able to cleave the IL-11R. However,
we demonstrated that NE and PR3, which do not cleave the
IL-6R, are able to generate sIL-11R.
Signaling of IL-6 via the sIL-6R is believed to account for the
pro-inflammatory functions of the cytokine, and specific inhibi-
tion of this trans-signaling pathway has been shown to be bene-
ficial in various animal models of human inflammatory diseases
(Waetzig and Rose-John, 2012). sgp130 is the natural inhibitor
of IL-6 trans-signaling (Jostock et al., 2001), and an Fc-dimerizedere transiently transfected with IL-11R. Cells were
independent experiments were quantified (mean ±
nd to Figure 1. Scale bars, 10 mm.
e was analyzed by flow cytometry.
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Figure 6. Trans-signaling via the sIL-11R Is
Blocked by sgp130Fc
(A) Ba/F3-gp130 cells were incubated with
10 ng/ml recombinant IL-11 and increasing
amounts of recombinant sIL-11R for 48 hr. Signif-
icant increased proliferation, compared to no
addition of sIL-11R, is indicated. Error bars indi-
cate mean ± SD. *p < 0.05; n = 3. RLU, relative light
units.
(B) Ba/F3-gp130 cells were incubated with
10 ng/ml recombinant IL-11, 1 mg/ml recombinant
sIL-11R, and increasing amounts of sgp130Fc.
Significant reduced proliferation, compared to no
addition of sgp130Fc, is indicated. Error bars
indicate mean ± SD. *p < 0.05; n = 3.
(C) HEK293 cells were transfected with IL-11R and
stimulated with ionomycin with or without pre-
incubation with GI or GW as indicated. The su-
pernatant was collected, and Ba/F3-gp130 cells
were incubated with the conditioned-cell super-
natant (IL-11R SN) in the presence or absence of
IL-11 for 48 hr. Error bars indicate mean ± SD. *p <
0.05; n = 3.
(D) Conditioned cell supernatant from IL-11R
expressing HEK293 cells stimulated with ion-
omycin (IL-11R SN Iono) was produced as
described for (C), and Ba/F3-gp130 cells were
incubated with this medium in the presence of
IL-11 and increasing amounts of sgp130Fc for
48 hr. Significant reduced proliferation, compared
to no addition of sgp130Fc, is indicated. Error bars
indicate mean ± SD. *p < 0.05; n = 3.
(E) Ba/F3-gp130 cells were serum starved for 2 hr
and then stimulated with conditionedmedium from
IL-11R-expressing HEK293 cells in the presence
or absence of IL-11 and sgp130Fc. Ba/F3-gp130
cells were lysed, and STAT3 phosphorylation was
analyzed by western blot. Western blots from three
independent experiments were quantified (mean ±
SD). *p < 0.05; ns, not significant.
See also Figure S4.version of sgp130 is currently in clinical development (Jones
et al., 2011; Waetzig and Rose-John, 2012). Therefore, we spec-
ulated that IL-11 trans-signaling via the sIL-11R would also be
blocked by sgp130Fc. Indeed, sgp130Fc inhibited cellular prolif-
eration induced by IL-11 trans-signaling and STAT3 activation
in a dose-dependent manner. Thus, the beneficial effects of
sgp130Fc seen in vivo might not solely depend upon inhibition
of IL-6 trans-signaling but could, at least in part, be due to
blockade of IL-11 trans-signaling.
In conclusion, we show that the IL-11R can undergo ectodo-
main shedding by ADAM10 and the serine proteases NE and
PR3 and that the sIL-11R, in combination with IL-11, is able to
induce trans-signaling via gp130. Using human serum samples
from healthy volunteers, we show that sIL-11R exists in human
serum. sIL-6R levels are known to be elevated during inflamma-1770 Cell Reports 14, 1761–1773, February 23, 2016 ª2016 The Authorstory diseases (Garbers et al., 2015), and
it appears likely that sIL-11R levels—
and, thus, IL-11 trans-signaling—could
be enhanced during disease. Our data
suggest that, if disease conditions drivenby IL-11 trans-signaling were defined, such conditions could
well be treated by the IL-6 trans-signaling inhibitor sgp130Fc
or its derivatives (Figure S6).
EXPERIMENTAL PROCEDURES
Cells and Reagents
Cells, cytokines, and other reagents have been described previously (Baran
et al., 2013; Chalaris et al., 2007; Garbers et al., 2014; Nitz et al., 2015). Details
are provided in the Supplemental Experimental Procedures.
Construction of IL-6R/IL-11R Chimeric Receptors and IL-11R
Deletion Variants
Chimeras of IL-6R and IL-11R have been described elsewhere (D€usterho¨ft
et al., 2014; Nitz et al., 2015). Stalk deletion variants of the IL-11R were con-
structed using standard splicing by overlapping extension PCR.
Figure 7. Cleavage of IL-6R and IL-11R by
Neutrophil-Derived Serine Proteases
(A) HepG2 cells were incubated for 2 hr with the
indicated concentrations of purified neutrophil-
derived serine proteases (NE, CG, and PR3) under
serum-free conditions. Levels of the sIL-6R in cell-
culture supernatants were determined by ELISA.
Error bars indicate mean ± SD.
(B) IL-11R expression on CD66b+ human primary
neutrophils from eight healthy volunteers was
analyzed via flow cytometry. Themean is indicated
by a horizontal line.
(C) HEK293 cells were transiently transfected with
a construct coding for the IL-11R. 48 hr post-
transfection, cells were incubated for 2 hr with
the indicated concentrations of purified neutro-
phil-derived serine proteases under serum-free
conditions. Soluble IL-11R from cell-culture
supernatants was precipitated with TCA and
analyzed by western blot. Additionally, cells were
lysed, and IL-11R levels in whole-cell lysates were
analyzed by western blot. GAPDH served as
loading control.
(D and E) HEK293 cells were transfected with
IL-11R or IL-6R and incubated with recombinant
NE or CG or left untreated. The supernatants were
collected, and Ba/F3-gp130 cells were incubated
with the conditioned cell supernatant (IL-11R SN or
IL-6R SN) in the presence or absence of IL-11 or
IL-6 for 48 hr where indicated. One of two per-
formed experiments with similar outcome is shown
(mean ± SD). *p < 0.05; ns, not significant.
(F–I) Serum samples from 21 healthy volunteers
were analyzed for IL-6, IL-11, sIL-6R, and sIL-11R.
Means are indicated by a horizontal line.
See also Figures S5 and S6.Ba/F3-gp130 Proliferation Assays
Proliferation of Ba/F3-gp130 cells was assessed using the Cell Titer Blue
Viability Assay (Promega) as described previously (Baran et al., 2013).
Protease Cleavage Assays
Analysis of cytokine receptor proteolysis has been described in detail else-
where (Baran et al., 2013; Garbers et al., 2011a).
Neutrophil-Derived Serine Protease Cleavage Assay
HEK293 cells were prepared as described for the ADAM Protease Shedding
Assay and stimulated with different concentrations of purified serine proteases
for 2 hr in serum-free media. Subsequently, supernatants and cells were har-
vested and separately analyzed by western blotting. HepG2 cells were seeded
in six-well plates. On the following day, cells were stimulated with different
concentrations of purified serine proteases for 2 hr in serum-free media.
Supernatants were harvested and analyzed by ELISA.
Precipitation of Soluble Receptors
1ml supernatant of stimulated HEK293 cells was harvested and centrifuged at
1,200 3 g to remove cells and subsequently at 18,000 3 g to remove cellularCell Reports 14, 1761–1773, Fdebris. Cleared supernatants were transferred
into new tubes, mixed with an equal volume of
20% trichloracetic acid (TCA), and incubated on
ice for 30 min. Protein precipitates were collected
by centrifugation at 18,000 3 g, the supernatants
were discarded, and the pellets were washed
with 350 ml ice-cold acetone. After a second centri-
fugation at 18,000 3 g, the acetone was removedand the pellets were allowed to dry. Afterward, the precipitated proteins
were boiled in Laemmli buffer and analyzed by western blot.
Western Blot Analysis
Detection of proteins via western blotting was performed as described previ-
ously (Baran et al., 2013; Garbers et al., 2014). Quantification of western blots
was performed with Image Studio Lite 5.2 (LI-COR Biosciences).
ELISA
An ELISA for the detection of the human IL-6R has been described previously
(Chalaris et al., 2007; Garbers et al., 2011a). An ELISA to detect sIL-11R was
performed as described previously (Blanc et al., 2000). The IL-6 ELISA was
from ImmunoTools, and the IL-11 ELISA was from R&D Systems.
Human Serum and Human PMNs
Ethics approval for this studywas obtained from the institutional review boards
of the Heinrich-Heine-University (study #3949) and the review board of the
medical faculty of Kiel University (study #D 487/13). All participants gave writ-
ten informed consent. Peripheral blood from healthy volunteers was collected
by venipuncture.ebruary 23, 2016 ª2016 The Authors 1771
Flow Cytometry Analysis
1 3 106 THP-1 cells were stimulated with 100 nM PMA or 1 mM ionomycin,
washed with fluorescence-activated cell sorting (FACS) buffer (0.5% BSA in
PBS), and stained with 1:100 diluted antibodies for 30 min on ice. After two
washing steps, cells were incubated with allophycocyanin (APC)-conjugated
secondary antibodies for 30min on ice. The cells were washed twice and resus-
pended in 500 ml FACSbuffer, and cell-surface expressionwas then analyzedby
flow cytometry. To analyze IL-11R on primary cells, heparinized whole human
blood was blocked with TruStain FcX (BioLegend), and the IL-11R expression
on PMNs was analyzed via staining with the anti-hIL-11R Ab N-20 and the
anti-human CD66b Ab (clone G10F5, BioLegend). Red blood cells were
removed, and the cells were fixedwithRBCLysis/Fixation Solution (BioLegend).
Confocal Microscopy
Confocal microscopy of transiently transfected HeLa cells was performed as
described previously (Garbers et al., 2014).
Statistical Analysis
Statistics were calculated using GraphPad Prism (GraphPad Software).
Data were analyzed by Student’s t test, and differences were indicated with
asterisks (p < 0.05). A one-sample t test was used to test for differences to
normalized data (e.g., comparison to a value of 1.0). For multiple comparisons,
p values were corrected via the Bonferroni correction.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.01.053.
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